RA Capital Management L.P. bought a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 967,000 shares of the company's stock, valued at approximately $9,186,000. RA Capital Management L.P. owned about 93.88% of Avalo Therapeutics as of its most recent SEC filing.
Several other large investors have also made changes to their positions in AVTX. Affinity Asset Advisors LLC lifted its stake in Avalo Therapeutics by 350.0% in the second quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company's stock valued at $561,000 after buying an additional 35,000 shares during the period. Logos Global Management LP acquired a new stake in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $6,722,000. Finally, Ikarian Capital LLC raised its position in shares of Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company's stock valued at $9,218,000 after acquiring an additional 915,629 shares during the period. Institutional investors and hedge funds own 87.06% of the company's stock.
Avalo Therapeutics Stock Performance
AVTX stock traded down $0.20 during midday trading on Thursday, hitting $9.80. 18,539 shares of the company's stock were exchanged, compared to its average volume of 205,894. The stock's fifty day moving average price is $11.13 and its 200-day moving average price is $10.91. Avalo Therapeutics, Inc. has a one year low of $3.95 and a one year high of $34.46.
Analyst Ratings Changes
Separately, HC Wainwright assumed coverage on shares of Avalo Therapeutics in a report on Thursday, October 24th. They issued a "neutral" rating on the stock.
Get Our Latest Research Report on Avalo Therapeutics
Avalo Therapeutics Company Profile
(
Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
See Also
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
